Potential signals of serious risks/new safety information identified by the FDA adverse event reporting system (FAERS)
GLP-1 Telemedicine Wisconsin: Understanding Wegovy and Zepbound The introduction of GLP-1 medications has revolutionized the field of obesity treatment
lactis than Lc
Lilly warns that products claiming to be retatrutide outside its trials may contain unknown ingredients, contaminants, too much or too little active material, or a different substance entirely
Patients should inform their doctor about all prescription medicines, over-the-counter drugs, herbal products, and nutritional supplements they are taking so that the prescriber can evaluate possible interactions and adjust therapy if needed
So, while the initial results are encouraging, its important to remember that a lot more research is needed before reaching any formal conclusions